Exclusive Journals Coverage articles provide quick insight and additional author perspectives on select studies recently published in Journal of Clinical Oncology and Journal of Oncology Practice.
Oct 27, 2014
A new study asks . . . are there additional biomarkers, independent of HER2, that can help to identify who might benefit from anti-HER2 monoclonal antibodies, specifically the combination of pertuzumab plus trastuzumab?
JCO Exclusive: Study Confirms Long-Lasting Benefits of Trastuzumab for Early-Stage HER2+ Breast Cancer
Oct 20, 2014
“We can now conclude for science in general, that adding trastuzumab to chemotherapy for patients with HER2-positive breast cancers significantly improves disease-free progression and overall survival, even in the long term,” said study first author, Edith A. Perez, MD . . .
Oct 06, 2014
The study found that, compared to survivors of CRC who were of a normal weight before diagnosis, survivors of CRC who were overweight before diagnosis had a 39% greater risk of being diagnosed with a second obesity-related cancer, whereas those who were obese had a 47% greater risk.
Sep 29, 2014
"An older patient with metastatic breast or colon cancer . . . likely has other issues like diabetes or hypertension for which they are taking drugs,” said Dr. Wolf. “The questions are—who’s responsible for managing those conditions, and who’s coordinating that care?”
Sep 23, 2014
I am originally from Manila, Philippines. My mother, a medical oncologist, inspired me to enter the field of oncology. She is my personal hero and idol, although she doesn't know this. She is hardworking, patient, and dedicated to her patients, and I feel the meaning of true vocation whenever I see her work. She is an instrument of healing. She's...
Sep 22, 2014
Among the four patients with DLBCL who had a complete response (CR), three are still alive, with ongoing survival-times ranging from nine to 22 months from treatment.
Sep 15, 2014
Among the important findings was that for every one “realistic” statement doctors made, they made three hopeful statements indicating that the treatment could bring positive outcomes, such as lengthening the life of the child.
Sep 02, 2014
A new study in the Journal of Clinical Oncology (JCO) found that patients who were admitted to hospice in the last three days of life were significantly more likely to have a hematologic malignancy, to be male, married, and younger than age 65.
Aug 25, 2014
The study found that five-year survivors of adolescent and adult Hodgkin lymphoma (HL) who received more than 36 gray (Gy) of radiation to the para-aortic lymph nodes and spleen had a significantly higher risk of developing diabetes mellitus . . .
Aug 11, 2014
The study showed that in 90% of patients with metastatic lung adenocarcinoma whose tumors contained common EGFR mutations (deletion in exon 19 or L858R), progression free survival (PFS) was 13.6 months for afatinib and 6.9 months for chemotherapy . . .